K-PAX Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2005-01-01
- Employees
- 11
- Market Cap
- -
- Website
- https://kpaxhealth.com
Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (100.0%)Methylphenidate Plus GWI-Nutrient Formula as a Treatment for Patients With Gulf War Illness
Phase 2
- Conditions
- Gulf War Illness
- Interventions
- Drug: Methyl-P plus GWI Nutrient Formula
- First Posted Date
- 2015-02-06
- Last Posted Date
- 2015-10-15
- Lead Sponsor
- K-PAX Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT02357030
- Locations
- 🇺🇸
Veterans Administration Palo Alto Health Care System (VAPAHCS), Palo Alto, California, United States
The Synergy Trial: Methylphenidate Plus a CFS-Specific Nutrient Formula as a Treatment for Chronic Fatigue Syndrome
Phase 2
- Conditions
- Chronic Fatigue Syndrome (CFS)Myalgic Encephalomyelitis (ME)
- Interventions
- Drug: Methyl-P plus Nutrient FormulaDrug: Methyl-P plus Nutrient matched placebos
- First Posted Date
- 2013-10-21
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- K-PAX Pharmaceuticals, Inc.
- Target Recruit Count
- 134
- Registration Number
- NCT01966276
- Locations
- 🇺🇸
Stanford Chronic Fatigue Syndrome/ME Initiative, Stanford, California, United States
🇺🇸Nova Southeastern University, Fort Lauderdale, Florida, United States
🇺🇸Susan Levine, MD, New York, New York, United States
News
No news found